Interview with Joan Alvarez, Country Manager, Lundbeck Philippines
You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it…
Address: 6/F Electra House Building, 115-117 Esteban Street, Legaspi Village, Makati City 1200 ,Philippines
Tel: +632 817-3021
Web: http://www.lundbeck.com/global
Lundbeck is a global pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
Lundbeck employs 5,900 people worldwide, 2,100 of whom are based in Denmark. Employees are present in 56 countries, and products are registered in more than 100 countries. The production facilities are located in Italy and Denmark and the research centres in Denmark and the USA.
Lundbeck Philippines started its operations as a representative office in 2003.
Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS). The most recently launched compounds include: Cipralex/Lexapro (depression), Ebixa (Alzheimer’s disease), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington’s disease), Serdolect (schizophrenia), Sabril (epilepsy) and Circadin (sleep disorders).
You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
Ramon Aristoza, acting President and CEO of PhilHealth, discusses the current challenges the organization is facing in terms of realizing the goal of universal healthcare for the Filipino population, their…
The election of maverick former mayor of Davao, Rodrigo Duterte to the Filipino presidency in May 2016 represented a dramatic departure from politics as usual and raised interesting questions about…
Ravinder S. Singha, the Managing Director of Firmlink Pharma, discusses the unique business model they offer to their clients, their key success factors in entering new and sometimes challenging markets,…
Jingle Garcia Diola, Executive Director at Firmlink Pharma, details the company’s value-added services and how they are positioning themselves as the business development partner of choice for large local and…
Javish Abichandani, Chief Executive Officer of AGlobal Care Inc. in the Philippines, outlines the company’s extensive product portfolio as well as their ambitions to bring more high-quality, affordable medications into…
Jose Augusto Pascual, President and CEO of PascualLab, sheds light on the company’s current footprint in the Philippines, as well as their ambitions to even further expand their manufacturing capabilities.…
Cheryl Maley, General Manager of Novartis Philippines, discusses the company’s operations in the country, their growing portfolio of products as well as their impressive focus on research and development in…
Meneleo Hernandez, Jr., President of Multicare, describes Lupin Pharma’s Multicare operations in the Philippines and how their niche business unit strategy and strategic partnerships create a sustainable business model that…
Ivan Alexi Arota, country manager of GE Healthcare Philippines, discusses the company’s extensive efforts to increase access to their innovative, affordable products throughout the country. He also expands on the…
Bakhuti Shengelia, Director Healthcare Systems of Novartis International AG, expands on Novartis’ initiatives to increase access to healthcare in emerging markets as well as the importance of transitioning towards value-based…
See our Cookie Privacy Policy Here
